
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

DALY II Japan/MB-CART2019.1 for DLBCL
Details : MB-CART2019.1 (Zamtocabtagene Autoleucel) is a cell & gene therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : MB-CART2019.1
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 17, 2025
